Safety, virology and pharmacokinetics of oseltamivir in infants with laboratory-confirmed influenza: A Phase I/II, prospective, open-label, multicentre clinical trial

Antiviral Therapy

Volumn 20, Issue 8, 2015, Pages 815-825

  Rath, Barbara A ^a   Brzostek, Jerzy ^b   Guillén, Sara ^c   Niranjan, Vis ^d   Chappey, Colombe ^e   Rayner, Craig R ^f,g   Clinch, Barry ^h  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Zespol Opieki Zdrowotnej W Debicy   (Poland)

^c HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^d RxMD   (India)

^e GENENTECH INC   (United States)

^f D3 Medicine LLC   (United States)

^g MONASH UNIVERSITY   (Australia)

^h ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; ANTIVIRUS AGENT;

ARTICLE; BRONCHIOLITIS; COHORT ANALYSIS; CONJUNCTIVITIS; CONTROLLED STUDY; COUGHING; CRACKLE; DIAPER DERMATITIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOOD REGURGITATION; HUMAN; INFANT; INFLUENZA; IRRITABILITY; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOROVIRUS INFECTION; OBSERVATIONAL STUDY; ORBIT CELLULITIS; OTITIS MEDIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RESPIRATORY SYNCYTIAL VIRUS INFECTION; ROTAVIRUS INFECTION; SEBORRHEIC DERMATITIS; SIDE EFFECT; SKIN ALLERGY; SKIN EDEMA; TACHYPNEA; THRUSH; VIRAL GASTROENTERITIS; VIROLOGY; VIRUS MUTATION; VIRUS SHEDDING; VOMITING; CLINICAL TRIAL; DRUG EFFECTS; IC50; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MICROBIAL SENSITIVITY TEST; MORTALITY; NEWBORN; PHYSIOLOGY; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; INHIBITORY CONCENTRATION 50; MALE; MICROBIAL SENSITIVITY TESTS; OSELTAMIVIR; TREATMENT OUTCOME; VIRUS SHEDDING;

EID: 84973573050     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2967     Document Type: Article

References (27)

1. Ampofo K, Gesteland PH, Bender J, et al. Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection. Pediatrics 2006; 118:2409-2417.
2. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med 2005; 353:2559-2567.
3. Loughlin J, Poulios N, Napalkov P, Wegmüller Y, Monto AS. A study of influenza and influenza-related complications among children in a large US health insurance plan database. Pharmacoeconomics 2003; 21:273-283.
4. Smith JR, Rayner CR, Donner B, Wollenhaupt M, Klumpp K, Dutkowski R. Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience. Adv Ther 2011; 28:927-959.
5. Tamiflu Summary of Product Characteristics (SPC). Electronic Medicines Compendium. (Accessed 18 November 2014.) Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000402/WC500033106.pdf
6. Tamiflu Prescribing Information (PI). U.S. Food and Drug Administration. (Accessed 18 November 2014.) Available from http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/021087s060,021246s043lbl.pdf
7. Oo C, Barrett J, Hill G, et al. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr Drugs 2001; 3:229-236.
8. Acosta EP, Kimberlin DW. Determination of appropriate dosing of influenza drugs in pediatric patients. Clin Pharmacol Ther 2010; 88:704-707.
9. Shi D, Yang D, Prinssen EP, Davies BE, Yan B. Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir. J Infect Dis 2011; 203:937-942.
10. Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol 2005; 1:447-471.
11. Assessment report for Tamiflu, 24 September 2009. European Medicines Agency. (Accessed 18 November 2014.) Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Assessment-Report---Variation/human/000402/WC500033109.pdf
12. Yang D, Pearce RE, Wang X, Gaedigk R, Wan YJ, Yan B. Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol 2009; 77:238-247.
13. Food and Drug Administration. Tamiflu prescribing information. (Accessed 18 November 2014.) Available from http://www.gene.com/download/pdf/tamiflu-prescribing.pdf
14. Kamal MA, Acosta EP, Kimberlin DW, et al. The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach. Clin Pharmacol Ther 2014; 96:380-389.
15. Kimberlin DW, Acosta EP, Prichard MN, et al. Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza. J Infect Dis 2013; 207:709-720.
16. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000; 355:1845-1850.
17. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283:1016-1024.
18. Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-24.
19. Rath B, von Kleist M, Tief F, et al. Virus load kinetics and resistance development during oseltamivir treatment in infants and children infected with Influenza A(H1N1) 2009 and Influenza B viruses. Pediatr Infect Dis J 2012; 31:899-905.
20. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127-133.
21. Siedler K, Skopnik H. Oseltamivir for treatment of influenza in infants less than one year: a retrospective analysis. Pediatr Infect Dis J 2010; 29:495-498.
22. Donner B, Bader-Weder S, Schwarz R, Peng MM, Smith JR, Niranjan V. Safety profile of oseltamivir during the 2009 influenza pandemic. Pharmacoepidemiol Drug Saf 2011; 20:532-543.
23. Rath BA, Blumentals WA, Miller MK, Starzyk K, Tetiurka B, Wollenhaupt M. A prospective observational study of oseltamivir safety and tolerability in infants and young children ≤24 months. Pharmacoepidemiol Drug Saf 2015; 24:286-296.
24. Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis 2010; 51:887-894.
25. Esposito S, Daleno C, Baldanti F, et al. Viral shedding in children infected by pandemic A/H1N1/2009 influenza virus. Virol J 2011; 8:349.
26. Li CC, Wang L, Eng HL, et al. Correlation of pandemic (H1N1) 2009 viral load with disease severity and prolonged viral shedding in children. Emerg Infect Dis 2010; 16:1265-1272.
27. Whitley RJ, Boucher CA, Lina B, et al. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). Clin Infect Dis 2013; 56:1197-1205.